YZYBIO-B schedules 28 Aug 2026 board session to approve 1H 2026 interim results
Bulletin Express
Aug 18
Wuhan YZY Biopharma Co., Ltd. (YZYBIO-B, HKEX: 02496) has fixed 28 August 2026 for a board meeting aimed at reviewing and approving the company’s interim financial statements for the six months ended 30 June 2026, according to an exchange filing dated 18 August 2026.
The agenda includes consideration of the 1H 2026 results, authorisation of their public release, and discussion of other routine business matters.
The meeting will be chaired by Dr. Zhou Pengfei, who serves concurrently as Chairman, Executive Director and Chief Executive Officer. The board currently comprises 2 executive directors, 5 non-executive directors and 4 independent non-executive directors, as set out in the announcement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.